Pancreatic Cancer Research

ResearcherJuntendo UniversityActive in the last 2 years

Naoto Gotohda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4468-5844; OpenAlex author ID A5050545841. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 19

  1. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  3. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  4. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  5. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Last author DOI 10.1001/jamaoncol.2024.5917↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  8. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  9. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  10. Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cas.15853↗
  11. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.3892/or.2022.8332↗
  12. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Co-author DOI 10.1111/cas.14914↗
  13. Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001539↗
  14. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001547↗
  15. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model. Co-author DOI 10.1186/s12876-020-01556-w↗
  16. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-53801-2↗
  17. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001369↗
  18. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. Co-author DOI 10.1097/mpa.0000000000001106↗
  19. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. Co-author DOI 10.1007/s00534-011-0371-z↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Motohiro Kojima · 8 shared papers, 2018–2023 · strength 0.96
  2. Katsuhiko Uesaka · 4 shared papers, 2019–2026 · strength 0.73
  3. Hirochika Toyama · 4 shared papers, 2019–2026 · strength 0.73
  4. Shinichiro Takahashi · 7 shared papers, 2011–2022 · strength 0.69
  5. Shin Kobayashi · 5 shared papers, 2018–2023 · strength 0.61
  6. Motokazu Sugimoto · 5 shared papers, 2018–2023 · strength 0.61
  7. Amane Takahashi · 3 shared papers, 2024–2026 · strength 0.57
  8. Akira Fukutomi · 2 shared papers, 2026 · strength 0.52
  9. Narikazu Boku · 2 shared papers, 2026 · strength 0.52
  10. Soichiro Morinaga · 3 shared papers, 2019–2026 · strength 0.44
  11. Horacio Cabral · 3 shared papers, 2020–2023 · strength 0.41
  12. Masashi Kudo · 3 shared papers, 2020–2023 · strength 0.41
  13. Shigeru Marubashi · 2 shared papers, 2025–2026 · strength 0.35
  14. Shintaro Yagi · 2 shared papers, 2024–2026 · strength 0.35
  15. Yusuke Sano · 2 shared papers, 2024–2026 · strength 0.35
  16. Keiko Kamei · 2 shared papers, 2024–2026 · strength 0.35
  17. Seiko Hirono · 2 shared papers, 2024–2026 · strength 0.35
  18. Etsuro Hatano · 2 shared papers, 2024–2026 · strength 0.35
  19. Makoto Ueno · 2 shared papers, 2024–2026 · strength 0.35
  20. Naoki Ikenaga · 2 shared papers, 2024–2026 · strength 0.35
  21. Michiaki Unno · 2 shared papers, 2024–2026 · strength 0.35
  22. Hiroaki Nagano · 2 shared papers, 2024–2025 · strength 0.31
  23. Kohei Nakata · 2 shared papers, 2024–2025 · strength 0.31
  24. Masafumi Nakamura · 2 shared papers, 2024–2025 · strength 0.31
  25. Hiroshi Kurahara · 2 shared papers, 2024–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.